Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).

被引：2
|
作者：
Veccia, Antonello
Burgio, Salvatore Luca
Di Lorenzo, Giuseppe
Ortega, Cinzia
Scognamiglio, Florinda
Aieta, Michele
Zustovich, Fable
Mattioli, Rodolfo
Mansueto, Giovanni
Facchini, Gaetano
Procopio, Giuseppe
D'Angelo, Alessandro
Spizzo, Gilbert
Donini, Maddalena
Bortolus, Roberto
Vicario, Giovanni
Zucali, Paolo A.
Basso, Umberto
Lo Re, Giovanni
Caffo, Orazio
机构：
[1] Santa Chiara Hosp, Trento, Italy
[2] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[3] Univ Naples Federico II, GU Canc Sect, Naples, Italy
[4] Fdn Piemonte Oncol, Inst Canc Res & Treatment, Turin, Italy
[5] Cardarelli Hosp, Neaples, Italy
[6] IRCCS CROB Ctr Riferimento Oncol Basilicata, Rionero In Vulture, Italy
[7] Veneto Inst Oncol IRCCS, Padua, Italy
[8] Santa Croce Hosp, Med Oncol Unit, Fano Pu, Italy
[9] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[10] NCI Pascale Fdn, Neaples, Italy
[11] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[12] Civil Hosp, Taormina, Italy
[13] Civil Hosp, Merano, Italy
[14] Ist Ospitalieri Cremona, Cremona, Italy
[15] Natl Canc Ctr CRO, Aviano, Italy
[16] Osped San Giacomo Apostolo Med Oncol, Castelfranco Veneto, Italy
[17] Humanitas Canc Ctr, Rozzano, Italy
[18] Ist Oncol Veneto IOV IRCCS, Padua, Italy
[19] Santa Maria Angeli Gen Hosp, Pordenone, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.92
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
92
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study)
    Veccia, Antonello
    Ortega, Cinzia
    di Lorenzo, Giuseppe
    La Russa, Francesca
    Burgio, Salvatore Luca
    Facchini, Gaetano
    Messina, Caterina
    Sacco, Cosimo
    Spizzo, Gilbert
    Aieta, Michele
    Lodde, Michele
    Mansueto, Giovanni
    Zucali, Paolo A.
    D'Angelo, Alessandro
    Iacovelli, Roberto
    Massari, Francesco
    Morelli, Franco
    Procopio, Giuseppe
    Ruatta, Fiorella
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Clinical outcome (CO) evaluation of very old (≥ 80 years) castration resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (DELPHI study).
    Maines, Francesca
    Burgio, Salvatore Luca
    Di Lorenzo, Giuseppe
    Scognamiglio, Florinda
    Zustovich, Fable
    Facchini, Gaetano
    Gamucci, Teresa
    Procopio, Giuseppe
    Bortolus, Roberto
    Lo Re, Giovanni
    La Russa, Francesca
    Bonetti, Andrea
    Messina, Caterina
    Lodde, Michele
    Perin, Alessandra
    Iacovelli, Roberto
    Pappagallo, Giovanni L.
    Veccia, Antonello
    Caffo, Orazio
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Clinical outcomes (CO) evaluation of very old (≥80 years) castration resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC): Updated results of an Italian multicenter retrospective study (cooperative group for DELPHI study)
    Caffo, O.
    Burgio, L. S.
    Di Lorenzo, G.
    Ortega, C.
    Scognamiglio, F.
    Mattioli, R.
    Mansueto, G.
    Facchini, G.
    Zustovich, F.
    Maines, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S699 - S699
  • [4] Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer
    Veccia, Antonello
    Caffo, Orazio
    De Giorgi, Ugo
    Di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Aieta, Michele
    Facchini, Gaetano
    Mansueto, Giovanni
    Mattioli, Rodolfo
    Procopio, Giuseppe
    Zagonel, Vittorina
    D'Angelo, Alessandro
    Spizzo, Gilbert
    Bortolus, Roberto
    Donini, Maddalena
    Lo Re, Giovanni
    Massari, Francesco
    Vicario, Giovanni
    Zucali, Paolo A.
    Alesini, Daniele
    Bonetti, Andrea
    Mucciarini, Claudia
    Nicodemo, Maurizio
    Berruti, Alfredo
    Fratino, Lucia
    Lodde, Michele
    Messina, Caterina
    Perin, Alessandra
    Santini, Daniele
    Sava, Teodoro
    Tucci, Marcello
    Basso, Umberto
    Maines, Francesca
    Burgio, Luca S.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2016, 12 (04) : 493 - 502
  • [5] Multiple rechallenges (ReCs) with docetaxel (DOC) as an option after first-line therapy in patients (pts) with castration-resistant prostate cancer (CRPC)
    Caffo, O.
    Brugnara, S.
    Caldara, A.
    Ferro, A.
    Frisinghelli, M.
    Murgia, V.
    Soini, B.
    Valduga, F.
    Veccia, A.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [6] Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 155 - 156
  • [7] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Clinical outcome (CO) and predictive factors (PRE) evaluation of young (≤60 years) castration-resistant prostate cancer (CRPC) patients, treated with docetaxel (DOC): Preliminary results of an Italian multicenter retrospective study (CYCLOP study).
    Caffo, Orazio
    Ortega, Cinzia
    Di Lorenzo, Giuseppe
    La Russa, Francesca
    Burgio, Salvatore Luca
    Messina, Caterina
    Facchini, Gaetano
    Iacovelli, Roberto
    Lodde, Michele
    Morelli, Franco
    Massari, Francesco
    Procopio, Giuseppe
    Zustovich, Fable
    Lo Re, Giovanni
    Pegoraro, Cristina
    Gamucci, Teresa
    Pappagallo, Giovanni L.
    Veccia, Antonello
    Maines, Francesca
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).
    Veccia, A.
    Caffo, O.
    Brugnara, S.
    Caldara, A.
    di Pasquale, M. C.
    Ferro, A.
    Frisinghelli, M.
    Murgia, V.
    Soini, B.
    Valduga, F.
    Pappagallo, G. L.
    Galligioni, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).
    Veccia, Antonello
    Caffo, Orazio
    Burgio, Salvatore Luca
    di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Mattioli, Rodolfo
    Mansueto, Giovanni
    Zustovich, Fable
    Aieta, Michele
    Facchini, Gaetano
    Procopio, Giuseppe
    D'Angelo, Alessandro
    Spizzo, Gilbert
    De Giorgi, Ugo
    De Placido, Sabino
    Ruatta, Fiorella
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345